Financial Data and Key Metrics Changes - The company reported a $10 million pull forward in revenue for Q2, which was a result of shifts in customer demand profiles [4][5] - The sales beat by $2 million, and the guidance for CRM and N was raised from low to mid-single digits to mid-single digits for the full year [4][5] - The backlog at the end of Q2 remained stable at approximately $700 million, providing good visibility for the next two quarters [5][6] Business Line Data and Key Metrics Changes - Cardiac Rhythm Management (CRM) growth was guided to mid-single digits, with a notable deceleration in CMV growth expected in the second half of the year [7][10] - CMV grew about 14% in Q1 and normalized for pull forward, also grew about 14% in Q2, implying a guidance of 7% for the second half [8][10] - The company expects mid-teens growth for CMV this year, indicating a strong year-over-year performance [10] Market Data and Key Metrics Changes - The renal denervation (RDN) market is currently small, estimated at less than $100 million globally, with potential growth to $200 million to $250 million next year [14][15] - The company sees opportunities in the tricuspid and mitral markets, which are part of the structural heart focus [34][35] Company Strategy and Development Direction - The company is focused on maintaining good visibility into customer demand and has a long-range planning process to ensure capacity meets future growth [18][40] - Recent acquisitions in coatings capabilities are expected to enhance customer relationships and create upselling opportunities [28][29] - The company aims to return to pre-COVID gross margins of 31% and operating margins of 18.8% through continuous improvement and operational efficiency [39][40] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the underlying strength of the markets they operate in, particularly in electrophysiology, structural heart, neurovascular, and neuromodulation [32] - The pricing environment is expected to be neutral on average, with 70% of the business under contract [33] Other Important Information - The company has a strong pipeline for M&A, with valuations trending lower than in previous years, and continues to seek strategic acquisitions [42][43] - The company is not currently planning any significant capacity expansions but has made recent expansions in Ireland [33] Q&A Session Summary Question: What is the outlook for cardiac rhythm management growth? - The guidance assumes 8% growth in the second half versus 2% in the first half, with new products and customer demand contributing to this acceleration [19] Question: How does the company view the renal denervation market? - The RDN market is seen as having potential tailwinds, with expectations of significant growth in the coming years [14][15] Question: What is the company's strategy regarding M&A? - The company is focused on strategic acquisitions that fill capability gaps and has a responsible approach to valuations [42][43]

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 暂定议程 报名：首届全球心血管大会 | 奖项报名倒计时 报名：首届全球骨科大会 | 奖项报名倒计时 2025年3月12日， 苏州无双医疗设备有限公司 （以下简称"无双医疗"）宣布 完成C轮近1.5亿元人民币融资 。 本轮融资由 天士力资本 领投，现有股东 启明创投、苏高新金控、康裕资本 继续加持。融资资金将主要用于公 司新一代产品研发和商业化 ，进一步巩固其在行业内的领先地位。 # 公司介绍 苏州无双医疗设备有限公司 成立于2017年7月11日，总部位于苏州高新区医疗器械产业园。公司是一家专注于 心脏节律管理（CRM） 相关医疗器械研发和产业化的硬科技企业。无双医疗致力于打造中国CRM高端医疗器 械品牌，产品线涵盖 植入式心律转复除颤器（ICD）、植入式心电事件监测器（ICM）以及植入式心脏起搏 器（Pacemaker） 等。 核心产品与技术 融资历程 天使轮： 2017年完成天使轮融资，投资方包括北极光创投等。 A轮： 2020年完成A轮融资，投资方包括启明创投，资金用于加速核心产品的研发和临床试验。 B轮： 2022年完成B轮融资，投资 ...